Company Overview and News
ERAMET annonce ce jour détenir 63,87 % du capital de la société Mineral Deposits Limited (MDL) dans le cadre de son offre publique d'achat (Offre). Le 10 juillet 2018, le Conseil d'Administration de MDL a par ailleurs recommandé à l'unanimité aux actionnaires de la société d'accepter l'Offre. MDL a également confirmé que l'ensemble de ses administrateurs ont l'intention d'accepter l'Offre en apportant les actions qu'ils détiennent.
ERAMET announces today that it now holds a relevant interest in 63.87% of the shares of Mineral Deposits Limited (MDL) in the framework of its all-cash takeover offer (Offer).
Following its press releases dated 27 April 2018, 14 May 2018, and 13 June 2018, ERAMET announces today that its all-cash offer (Offer) for all of the fully-paid ordinary shares in MDL that it does not already own is declared unconditional.
Kenmare Resources plc is pleased to announce that Mr Clever Fonseca has agreed to join the Company's Board as an independent Non-Executive Director, effective 1 July 2018. Mr Fonseca has worked in the titanium industry for over thirty five years and has extensive knowledge and board-level management experience of mineral sands mining.
MNLDF MDL KMR KMRPF
Groupe ERAMET : augmentation à 1,75 dollar australien, prix final et définitif de l'Offre Publique d'Achat sur les actions de la société Mineral Deposits Limited (MDL)
VANCOUVER, British Columbia, May 23, 2018 (GLOBE NEWSWIRE) -- European Electric Metals Inc. (TSX-V:EVX) (“EVX” or “the Company”) is pleased to announce that it has signed an agreement to acquire an exploration application in Portugal for an advanced stage copper asset with historic production.
MNLDF RTPPF RIO RIO LUNMF RIO PWRMF RTNTF LUNCF LUN EVXXF MDL
Following its press release dated 27 April 2018, ERAMET today announces that its off-market takeover offer to acquire all of the issued shares in Mineral Deposits Limited (MDL) that it does not already own for A$1.46 cash per share (Offer) is now open for acceptance by MDL shareholders.
Mineral Deposits (MDL) chairman Nic Limb has responded negatively to Eramet’s unsolicited offer to acquire MDL for $287.5 million at $1.46/share, calling the offer “grossly inadequate” and urging shareholders to reject it.
Mineral Deposits Limited (ASX:MDL) is a leading ASX gainer after fielding a takeover offer from French-based, global mining company ERAMET SA (FRA:ER7).
MNLDF MDL ERA
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...